Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Tumor-infiltrating lymphocytes for adoptive cell therapy : recent advances, challenges, and future directions. / Granhøj, Joachim Stoltenborg; Witness Præst Jensen, Agnete; Presti, Mario; Met, Özcan; Svane, Inge Marie; Donia, Marco.
I: Expert Opinion on Biological Therapy, Bind 22, Nr. 5, 2022, s. 627-641.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Tumor-infiltrating lymphocytes for adoptive cell therapy
T2 - recent advances, challenges, and future directions
AU - Granhøj, Joachim Stoltenborg
AU - Witness Præst Jensen, Agnete
AU - Presti, Mario
AU - Met, Özcan
AU - Svane, Inge Marie
AU - Donia, Marco
N1 - Publisher Copyright: © 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Introduction: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a highly personalized type of cancer immunotherapy. TIL-based ACT exploits naturally occurring TILs, derived from the patients’ tumor. This treatment has shown consistent clinical responses in melanoma, and recent results point toward a potential use in multiple cancer diagnoses. However, several limitations have restricted the clinical development and adaptation of TIL-based ACT. Areas covered: In this review, we present the principles of TIL-based ACT and discuss the most significant limitations for therapeutic efficacy and its widespread application. The topics of therapeutic resistance (both innate and acquired), treatment-related toxicity, and the novel research topic of metabolic barriers in the tumor microenvironment (TME) are covered. Expert opinion: There are many ongoing areas of research focusing on improving clinical efficacy and optimizing TIL-based ACT. Many strategies have shown a great potential, particularly strategies advancing TIL efficacy (such as increasing and harnessing ex vivo the sub-population of tumor-reactive TILs) and manufacturing processes. Novel approaches can help overcome current limitations and potentially result in TIL-based ACT entering the mainstream of cancer therapy across tumor types.
AB - Introduction: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a highly personalized type of cancer immunotherapy. TIL-based ACT exploits naturally occurring TILs, derived from the patients’ tumor. This treatment has shown consistent clinical responses in melanoma, and recent results point toward a potential use in multiple cancer diagnoses. However, several limitations have restricted the clinical development and adaptation of TIL-based ACT. Areas covered: In this review, we present the principles of TIL-based ACT and discuss the most significant limitations for therapeutic efficacy and its widespread application. The topics of therapeutic resistance (both innate and acquired), treatment-related toxicity, and the novel research topic of metabolic barriers in the tumor microenvironment (TME) are covered. Expert opinion: There are many ongoing areas of research focusing on improving clinical efficacy and optimizing TIL-based ACT. Many strategies have shown a great potential, particularly strategies advancing TIL efficacy (such as increasing and harnessing ex vivo the sub-population of tumor-reactive TILs) and manufacturing processes. Novel approaches can help overcome current limitations and potentially result in TIL-based ACT entering the mainstream of cancer therapy across tumor types.
KW - Adoptive cell therapy
KW - cell therapy
KW - cellular immunotherapy
KW - resistance to immunotherapy
KW - TILs
KW - tumor-infiltrating lymphocytes
U2 - 10.1080/14712598.2022.2064711
DO - 10.1080/14712598.2022.2064711
M3 - Review
C2 - 35414331
AN - SCOPUS:85128843597
VL - 22
SP - 627
EP - 641
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
IS - 5
ER -
ID: 313648493